文献速递皮肤肿瘤

肾移植受者黑色素瘤的危险因素

Risk Factors for Melanoma in Renal Transplant Recipients.
PubMed 文献 · JAMA Dermatol · 2017-01-01

基于美国肾脏数据系统(USRDS)2004至2012年105 174例肾移植受者的队列研究,488例(0.4%)移植后发生黑色素瘤。受者年龄较大、男性、白人、活体供者及西罗莫司或环孢素治疗与风险升高相关;年龄标准化相对率为4.9,中位发生时间为1.45年。

要点

  • 肾移植受者黑色素瘤风险高于一般人群,年龄标准化相对率为4.9。
  • 受者年龄、男性、白人、活体供者及西罗莫司或环孢素治疗与风险升高相关。
  • 发生黑色素瘤者的中位时间为移植后1.45年,应加强早期皮肤监测。

核心结论

  • 肾移植受者发生黑色素瘤的风险高于一般人群,所识别的危险因素可指导临床对此脆弱人群的照护。

研究设计与样本

  • 这是一项基于美国肾脏数据系统(USRDS)2004至2012年肾移植受者的全国性数据登记队列研究。
  • 共纳入105 174例患者,其中64 151例(60.7%)为男性,平均(SD)年龄49.6(15.3)岁。
  • 排除标准包括移植前黑色素瘤史、既往肾移植、2012年后或2004年前移植;数据分析于2015至2016年进行。

主要发现

  • 488例(0.4%)移植后出现黑色素瘤记录。
  • 发生与未发生黑色素瘤者相比:受者平均(SD)年龄60.5(10.2)对49.7(15.3)岁,P<.001;供者42.6(15.0)对39.2(15.1)岁,P<.001。
  • 男性71.5%对60.7%,P<.001;受者白人96.1%对66.5%,P<.001;供者白人92.4%对82.9%,P<.001。
  • HLA错配少于4个44.9%对37.1%,P=.001;活体供者44.7%对33.7%,P<.001;西罗莫司22.3%对13.2%,P<.001;环孢素4.9%对3.2%,P=.04。
  • 生存分析中:受者年龄每增1岁HR 1.06(95%CI 1.05-1.06),P<.001;男性HR 1.53(95%CI 1.25-1.88),P<.001;活体供者HR 1.35(95%CI 1.11-1.64),P=.002;西罗莫司HR 1.54(95%CI 1.22-1.94),P<.001;环孢素HR 1.93(95%CI 1.24-2.99),P=.004。

关键数值与推荐

  • 与监测、流行病学和最终结果(SEER)患者相比,USRDS患者各年度年龄标准化黑色素瘤相对率为4.9。
  • 发生黑色素瘤者的Kaplan-Meier中位发生时间为1.45年(95%CI 1.31-1.70年)。

临床怎么用

  • 对肾移植受者应识别高龄、男性、白人、活体供者及使用西罗莫司或环孢素等高风险特征并加强皮肤监测。
  • 移植后早期即应关注黑色素瘤风险,因中位发生时间约为1.45年。

局限性

  • 本研究为基于理赔编码的登记数据队列研究,黑色素瘤诊断依赖计费编码,可能存在漏诊或错分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Melanoma risk factors and incidence in renal transplant recipients can inform decision making for both patients and clinicians. OBJECTIVE: To determine risk factors and characteristics of renal transplant recipients who develop melanoma. DESIGN, SETTING, AND PARTICIPANTS: This cohort study of a large national data registry used a cohort of renal transplant recipients from the United States Renal Data System (USRDS) database from the years 2004 through 2012. Differences in baseline characteristics between those who did and did not develop melanoma were examined, and a survival analysis was performed. Patients with renal transplants who received a diagnosis of melanoma according to any inpatient or outpatient claim associated with a billing code for melanoma were included. A history of pretransplant melanoma, previous kidney transplantation, or transplantation after 2012 or before 2004 were exclusion criteria. The data analysis was conducted from 2015 to 2016. EXPOSURE: Receipt of a renal transplant. MAIN OUTCOMES AND MEASURES: Incidence and risk factors for melanoma. RESULTS: Of 105 174 patients (64 151 [60.7%] male; mean [SD] age, 49.6 [15.3] years) who received kidney transplants between 2004 and 2012, 488 (0.4%) had a record of melanoma after transplantation. Significant risk factors for developing melanoma vs not developing melanoma included older age among recipients (mean [SD] age, 60.5 [10.2] vs 49.7 [15.3] years; P < .001) and donors (42.6 [15.0] vs 39.2 [15.1] years; P < .001), male sex (71.5% vs 60.7%; P < .001), recipient (96.1% vs 66.5%; P < .001) and donor (92.4% vs 82.9%; P < .001) white race, less than 4 HLA mismatches (44.9% vs 37.1%; P = .001), living donors (44.7% vs 33.7%; P < .001), and sirolimus (22.3% vs 13.2%; P < .001) and cyclosporine (4.9% vs 3.2%; P = .04) therapy. Risk factors significant on survival analysis included older recipient age (hazard ratio [HR] per year, 1.06; 95% CI, 1.05-1.06; P < .001), recipient male sex (HR, 1.53; 95% CI, 1.25-1.88; P < .001), recipient white race, living donors (HR, 1.35; 95% CI, 1.11-1.64; P = .002), and sirolimus (HR, 1.54; 95% CI, 1.22-1.94; P < .001) and cyclosporine (HR, 1.93; 95% CI, 1.24-2.99; P = .004) therapy. The age-standardized relative rate of melanoma in USRDS patients compared with Surveillance, Epidemiology, and End Results patients across all years was 4.9. A Kaplan-Meier estimate of the median time to melanoma among those patients who did develop melanoma was 1.45 years (95% CI, 1.31-1.70 years). CONCLUSIONS AND RELEVANCE: Renal transplant recipients had greater risk of developing melanoma than the general population. We believe that the risk factors we identified can guide clinicians in providing adequate care for patients in this vulnerable group.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Ascha M, Ascha MS, Tanenbaum J, et al. Risk Factors for Melanoma in Renal Transplant Recipients. JAMA Dermatol. 2017. PMID: 28746700. doi:10.1001/jamadermatol.2017.2291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。